Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4

被引:1222
作者
Pålsson-McDermott, EM [1 ]
O'Neill, LAJ [1 ]
机构
[1] Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland
关键词
CD14; LPS; Mal; MyD88; TLR4;
D O I
10.1111/j.1365-2567.2004.01976.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
An understanding of lipopolysaccharide (LPS) signal transduction is a key goal in the effort to provide a molecular basis for the lethal effect of LPS during septic shock and point the way to novel therapies. Rapid progress in this field during the last 6 years has resulted in the discovery of not only the receptor for LPS - Toll-like receptor 4 (TLR4) - but also in a better appreciation of the complexity of the signalling pathways activated by LPS. Soon after the discovery of TLR4, the formation of a receptor complex in response to LPS, consisting of dimerized TLR4 and MD-2, was described. Intracellular events following the formation of this receptor complex depend on different sets of adapters. An early response, which is dependent on MyD88 and MyD88-like adapter (Mal), leads to the activation of nuclear factor-kappaB (NF-kappaB). A later response to LPS makes use of TIR-domain-containing adapter-inducing interferon-beta (TRIF) and TRIF-related adapter molecule (TRAM), and leads to the late activation of NF-kappaB and IRF3, and to the induction of cytokines, chemokines, and other transcription factors. As LPS signal transduction is an area of intense research and rapid progress, this review is intended to sum up our present understanding of the events following LPS binding to TLR4, and we also attempt to create a model of the signalling pathways activated by LPS.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 100 条
[1]
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function [J].
Adachi, O ;
Kawai, T ;
Takeda, K ;
Matsumoto, M ;
Tsutsui, H ;
Sakagami, M ;
Nakanishi, K ;
Akira, S .
IMMUNITY, 1998, 9 (01) :143-150
[2]
Lipopolysaccharide interaction with cell surface toll-like receptor 4-MD-2: Higher affinity than that with MD-2 or CD14 [J].
Akashi, S ;
Saitoh, S ;
Wakabayashi, Y ;
Kikuchi, T ;
Takamura, N ;
Nagai, Y ;
Kusumoto, Y ;
Fukase, K ;
Kusumoto, S ;
Adachi, Y ;
Kosugi, A ;
Miyake, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (07) :1035-1042
[3]
Bopst M, 2001, EUR J IMMUNOL, V31, P1935, DOI 10.1002/1521-4141(200106)31:6&lt
[4]
1935::AID-IMMU1935&gt
[5]
3.0.CO
[6]
2-N
[7]
Boyle WA, 2000, CIRC RES, V87, pE18
[8]
ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance [J].
Brint, EK ;
Xu, DM ;
Liu, HY ;
Dunne, A ;
McKenzie, ANJ ;
O'Neill, LAJ ;
Liew, FY .
NATURE IMMUNOLOGY, 2004, 5 (04) :373-379
[9]
Inhibition of interleukin 1 receptor/toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4 [J].
Burns, K ;
Janssens, S ;
Brissoni, B ;
Olivos, N ;
Beyaert, R ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (02) :263-268
[10]
MyD88, an adapter protein involved in interleukin-1 signaling [J].
Burns, K ;
Martinon, F ;
Esslinger, C ;
Pahl, H ;
Schneider, P ;
Bodmer, JL ;
Di Marco, F ;
French, L ;
Tschopp, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :12203-12209